Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback